Menopause is a natural stage in a woman's life that can be associated with symptoms such as hot flashes, night sweats, sleep problems, and vaginal dryness. Menopausal hormone therapy is commonly used to relieve these symptoms. In women with an intact uterus, progesterone must be used together with estrogen to protect the lining of the uterus.
The purpose of this study is to compare two commonly used progesterone treatment methods in women receiving menopausal hormone therapy. All participants will use transdermal estradiol gel, and they will be randomly assigned to receive either oral dydrogesterone or vaginal micronized progesterone.
This prospective randomized controlled study will evaluate the effects of these treatments on endometrial thickness, menopausal symptoms, vaginal health parameters, bleeding patterns, and quality of life over a 12-month follow-up period.
The results of this study may help determine the most appropriate progesterone regimen for women undergoing menopausal hormone therapy.
Women aged 45-60 years
Postmenopausal status (absence of menstruation for ≥12 months)
Intact uterus
Presence of menopausal symptoms requiring menopausal hormone therapy
Unexplained vaginal bleeding
History of breast cancer or endometrial cancer
Known hypersensitivity to study medications
History of thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism)